Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas

CD19CAR T cells facilitate a transformational treatment in various relapsed and refractory aggressive B-lineage cancers. In general, encouraging response rates have been observed in B-lineage-derived non-Hodgkin’s lymphomas treated with CD19CAR T cells. The major cause of death in heavily pretreated...

Descripción completa

Detalles Bibliográficos
Autores principales: Atar, Daniel, Mast, Anna-Sophia, Scheuermann, Sophia, Ruoff, Lara, Seitz, Christian Martin, Schlegel, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599140/
https://www.ncbi.nlm.nih.gov/pubmed/36289682
http://dx.doi.org/10.3390/biomedicines10102420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599140/
https://www.ncbi.nlm.nih.gov/pubmed/36289682
http://dx.doi.org/10.3390/biomedicines10102420

Ejemplares similares